ANDA 210714, held by Saba Ilay Sanayi. Isosulfan Blue.
As of Nov 16, 2026, ANDA 210714 (Isosulfan Blue), held by Saba Ilay Sanayi, was first approved by FDA on Jan 16, 2019, with 0 approved supplements and 0 published complete response letters.
Isosulfan blue injection upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities. 1.1 Lymphatic Vessel Delineation Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 16, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Isosulfan Blue50MG/5ML (10MG/ML) · solution;subcutaneous | Isosulfan Blue | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters